Recombinant Human Insulin Market
Recombinant Human Insulin Market Forecasts to 2030 - Global Analysis By Product (Short-Acting Human Insulin, Intermediate-Acting Human Insulin and Premixed Human Insulin), Brand (Humulin R, Novolin R, Humulin N, Novolin N and Other Brands), Distribution Channel and By Geography
According to Stratistics MRC, the Global Recombinant Human Insulin Market is accounted for $20.97 billion in 2024 and is expected to reach $28.91 billion by 2030 growing at a CAGR of 5.5% during the forecast period. Recombinant human insulin is a synthetic form of the hormone that is made using recombinant DNA technology, mostly in yeast (Saccharomyces cerevisiae) or genetically modified bacteria like Escherichia coli. It was created as a more effective and safe substitute for the widely used insulin derived from animal sources prior to its introduction. Moreover, recombinant human insulin helps diabetics control their blood glucose levels by simulating the body's natural production of the hormone. In order to produce it, the human insulin gene is inserted into microbial cells, which subsequently use regulated fermentation processes to synthesize the protein.
According to the International Diabetes Federation (IDF), the number of adults with diabetes is projected to reach 643 million by 2030.
Market Dynamics:
Driver:
Growing prevalence of diabetes
The market for recombinant human insulin is largely driven by the rising prevalence of diabetes worldwide, especially type 1 and insulin-dependent type-2 diabetes. The demand for insulin-based treatments is predicted to rise dramatically as the number of people with diabetes rises to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation (IDF). Additionally, diabetes is also becoming more common due to sedentary lifestyles, poor diets, and altered lifestyles, which increases the need for insulin to maintain glycemic control.
Restraint:
Expensive insulin therapy
The high cost of recombinant human insulin is one of the biggest barriers to its market, limiting accessibility, particularly in low- and middle-income countries (LMICs). Because of costly production methods, monopolistic pricing tactics by large pharmaceutical companies, and patent protections, prices are still an issue even with the availability of bio-similar insulin. The World Health Organization (WHO) claims that a large number of people in developing nations cannot afford insulin, which results in inadequate disease management and a rise in complications associated with diabetes. Furthermore, limiting the widespread use of insulin therapy is the high out-of-pocket costs, which can strain healthcare systems.
Opportunity:
Developments in insulin delivery system technology
Technological advancements in insulin delivery present substantial growth prospects. Precision, convenience, and patient adherence are all improved by the development of artificial pancreas systems, insulin pumps, smart insulin pens, and continuous glucose monitoring (CGM) devices. By offering automated dosing adjustments and real-time glucose monitoring, wearable and automated insulin delivery systems lower the risk of hypoglycemia and blood sugar swings. Moreover, the use of recombinant human insulin in sophisticated therapeutic solutions will be fueled by advancements in digital healthcare and smart medical devices.
Threat:
Strict approval procedure for regulation
Strict regulatory oversight of recombinant human insulin products results in lengthy approval processes and expensive compliance expenses. Insulin production must meet strict safety, efficacy, and quality standards set by regulatory bodies like the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and China's National Medical Products Administration (NMPA). Additionally, the lengthy comparability studies, clinical trials, and post-market surveillance required for bio-similar insulin approvals can cause delays in product launches and raise operating expenses.
Covid-19 Impact:
Due to the disruption of global supply chains, the delay of clinical trials, and the strain on healthcare systems, the COVID-19 pandemic had a major effect on the market for recombinant human insulin. Insulin production and distribution were delayed, and raw material shortages resulted from lockdowns and transportation restrictions, which impacted market availability, especially in low- and middle-income nations. Financial limitations and job losses also made it harder for patients to afford insulin therapy, which decreased adherence. However, the pandemic also hastened the adoption of home-based diabetes management programs and telemedicine, which has increased demand for insulin delivery devices that can be used by the patients themselves, such as insulin pumps and pens.
The Premixed Human Insulin segment is expected to be the largest during the forecast period
The Premixed Human Insulin segment is expected to account for the largest market share during the forecast period. Premixed human insulin improves patient compliance by reducing the number of daily injections and simplifying dosing schedules by combining precise ratios of short-acting and intermediate-acting insulin. For people with type 2 diabetes who need both basal and prandial glycemic control, this formulation is especially helpful. Moreover, the use of premixed human insulin has increased due to the rising incidence of diabetes worldwide and the growing need for insulin treatments that are easy to use, thereby securing its market leadership.
The Humulin R segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Humulin R segment is predicted to witness the highest growth rate. Humulin R is short-acting insulin that is frequently used to control postprandial blood glucose levels. Because of its quick onset of action, it is an essential part of intensive insulin therapy. Key drivers of its market expansion include the rising incidence of type 2 diabetes, the growing use of self-administration insulin delivery systems, and the rising need for bio-similar insulin formulations. Additionally, its robust growth trajectory has also been aided by continuous developments in insulin pump technology and the incorporation of Humulin R into hybrid closed-loop systems.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, driven by the high rate of diabetes, the sophisticated medical system, and the widespread use of cutting-edge insulin delivery technologies. The region benefits from a growing number of diabetics, especially in the US, well-established reimbursement policies, and rising demand for biosimilar insulin. North America's dominance is further reinforced by the existence of top insulin producers, ongoing R&D expenditures, and government programs to improve diabetes care. Furthermore, the region's market is growing steadily due in part to consumers' growing preference for smart insulin pens and pumps.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by nations like China, India, and Japan's expanding access to insulin therapies, rising healthcare costs, and the fast-growing number of people with diabetes. Growing use of bio-similar insulin, government programs to upgrade the infrastructure for diabetes care and the existence of a sizable untapped patient base are all driving market expansion. Moreover, growing urbanization, lifestyle changes that contribute to a higher prevalence of diabetes and growing awareness of self-administration insulin delivery devices all support the market's robust growth trajectory in this region.
Key players in the market
Some of the key players in Recombinant Human Insulin market include AstraZeneca Ltd, Eli Lilly and Company, Sanofi S.A, Gan & Lee Pharmaceuticals, Ltd, Dongbao Enterprise Group Co Ltd., Merck KGaA, Biocon Limited, Zhuhai United Laboratories Co., Ltd, Duopharma Marketing Sdn Bhd, Julphar Gulf Pharmaceutical Industries, Novo Nordisk A/S, Sigma-Aldrich Inc, Bioton S.A, Pfizer Inc and Wanbang Biopharmaceuticals Co., Ltd.
Key Developments:
In September 2024, Biocon Ltd said it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its 'GLP-1' products for treating diabetes and chronic weight management in select countries of the Middle East. Under the agreement, the company will develop and manufacture the products and Tabuk Pharmaceuticals -- a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region.
In July 2024, Merck has signed an agreement to sell its global Surface Solutions business unit to Global New Material International Holdings Ltd. for € 665 million in cash. Merck intends to use the net proceeds from the divestment to further strengthen its strategic core businesses.
In March 2024, AstraZeneca Pharma India and Mankind Pharma has entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and long-acting beta-agonist and will continue to be the marketing authorisation holder (MAH) and import license.
Products Covered:
• Short-Acting Human Insulin
• Intermediate-Acting Human Insulin
• Premixed Human Insulin
Brands Covered:
• Humulin R
• Novolin R
• Humulin N
• Novolin N
• Other Brands
Distribution Channels Covered:
• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Recombinant Human Insulin Market, By Product
5.1 Introduction
5.2 Short-Acting Human Insulin
5.3 Intermediate-Acting Human Insulin
5.4 Premixed Human Insulin
6 Global Recombinant Human Insulin Market, By Brand
6.1 Introduction
6.2 Humulin R
6.3 Novolin R
6.4 Humulin N
6.5 Novolin N
6.6 Other Brands
7 Global Recombinant Human Insulin Market, By Distribution Channel
7.1 Introduction
7.2 Hospitals
7.3 Retail Pharmacies
7.4 Online Pharmacies
7.5 Other Distribution Channels
8 Global Recombinant Human Insulin Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 AstraZeneca Ltd
10.2 Eli Lilly and Company
10.3 Sanofi S.A
10.4 Gan & Lee Pharmaceuticals, Ltd
10.5 Dongbao Enterprise Group Co Ltd.
10.6 Merck KGaA
10.7 Biocon Limited
10.8 Zhuhai United Laboratories Co., Ltd
10.9 Duopharma Marketing Sdn Bhd
10.10 Julphar Gulf Pharmaceutical Industries
10.11 Novo Nordisk A/S
10.12 Sigma-Aldrich Inc
10.13 Bioton S.A
10.14 Pfizer Inc
10.15 Wanbang Biopharmaceuticals Co., Ltd
List of Tables
1 Global Recombinant Human Insulin Market Outlook, By Region (2022-2030) ($MN)
2 Global Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
3 Global Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
4 Global Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
5 Global Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
6 Global Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
7 Global Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
8 Global Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
9 Global Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
10 Global Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
11 Global Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
12 Global Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
13 Global Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
14 Global Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
15 Global Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
16 Global Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
17 North America Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
18 North America Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
19 North America Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
20 North America Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
21 North America Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
22 North America Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
23 North America Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
24 North America Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
25 North America Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
26 North America Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
27 North America Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
28 North America Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
29 North America Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
30 North America Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
31 North America Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
32 North America Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
33 Europe Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
34 Europe Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
35 Europe Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
36 Europe Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
37 Europe Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
38 Europe Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
39 Europe Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
40 Europe Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
41 Europe Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
42 Europe Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
43 Europe Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
44 Europe Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
45 Europe Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
46 Europe Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
47 Europe Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
48 Europe Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
49 Asia Pacific Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
50 Asia Pacific Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
51 Asia Pacific Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
52 Asia Pacific Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
53 Asia Pacific Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
54 Asia Pacific Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
55 Asia Pacific Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
56 Asia Pacific Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
57 Asia Pacific Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
58 Asia Pacific Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
59 Asia Pacific Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
60 Asia Pacific Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
61 Asia Pacific Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
62 Asia Pacific Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
63 Asia Pacific Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
64 Asia Pacific Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
65 South America Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
66 South America Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
67 South America Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
68 South America Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
69 South America Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
70 South America Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
71 South America Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
72 South America Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
73 South America Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
74 South America Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
75 South America Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
76 South America Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
77 South America Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
78 South America Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
79 South America Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
80 South America Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
81 Middle East & Africa Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
82 Middle East & Africa Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
83 Middle East & Africa Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
84 Middle East & Africa Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
85 Middle East & Africa Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
86 Middle East & Africa Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
87 Middle East & Africa Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
88 Middle East & Africa Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
89 Middle East & Africa Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
90 Middle East & Africa Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
91 Middle East & Africa Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
92 Middle East & Africa Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
93 Middle East & Africa Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
94 Middle East & Africa Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
95 Middle East & Africa Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
96 Middle East & Africa Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
